TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03816137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 763 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 763 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMC011 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMC011 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMC011 SOSIP
Description: HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
Study: NCT01748552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922083
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922083
Description: Administered orally as capsules
Study: NCT02738398

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Study: NCT03137407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01936402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of chest compression depth
Description: An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of chest compression depth
Description: An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
Study: NCT02252276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental (proprioception exercises, muscle strengthening, joint mobilization)
Description: The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control (proprioception exercises, muscle strengthening)
Description: The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
Study: NCT03096145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling 1 session
Description: 1 call coaching session for nonsmokers that will be piloted and adapted in this study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile texting
Description: nonsmokers will receive 3-5 text messages for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health incentive
Description: Smokers receive a $25 gift card if they call the quitline
Study: NCT00908856

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: marrow stromal cells
Description: a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
Study: NCT00329940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01727778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GRP78 monoclonal IgM antibody PAT-SM6
Study: NCT00595777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPAT© Educational Package
Description: The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
Study: NCT00625274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg Oral
Study: NCT02041442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical mapping of the urinary bladder
Study: NCT01171170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin paclitaxel bevacizumab
Description: paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment plus nitroglycerin
Description: paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
Study: NCT00625274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30mg Oral
Study: NCT04452526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Receive reminder letter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Receive reminder letter
Study: NCT01442129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPC Intramyocardial injection
Description: Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Control Solution
Description: Injection of control solution during the LVAD implantation.
Study: NCT01856946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4,000 IU vitamin D3
Description: two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
Study: NCT01810159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and Resources
Study: NCT00309777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin once daily
Study: NCT03662152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam roller
Description: Foam roller massage after DOMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration foam roller
Description: Foam roller massage with vibration after DOMS
Study: NCT00149825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 5 to 20 mg for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 5 to 20 mg for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI
Description: Cognitive Behavioral Treatment for Insomnia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CTRL
Description: Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
Study: NCT02186327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Health Coaching
Description: Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
Study: NCT01676376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eSVS Mesh treated saphenous vein graft
Description: During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eSVS Mesh treated saphenous vein graft
Description: During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control saphenous vein graft
Description: During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
Study: NCT04408521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEUROFEEDBACK
Description: EEG recording during alpha-related TV viewing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: EEG recording during passive TV viewing
Study: NCT00592501

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton/Photon Radiotherapy
Description: Given once a day, five days a week, for seven weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
Study: NCT00862381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%
Study: NCT00604448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advise
Description: Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advise
Description: Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet enriched with a meal containing pulses
Description: Subjects in pulse group will consume the commercially available pulses for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet enriched with a meal containing pulses
Description: Subjects in pulse group will consume the commercially available pulses for 8 weeks
Study: NCT02638428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Study: NCT00625274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40mg Oral
Study: NCT01157858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 2.5 mg every day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: 40 mg every 28 days IM
Study: NCT02706626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brigatinib
Description: Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brigatinib
Description: Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brigatinib
Description: Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
Study: NCT03670745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An electronic self-administered pre-visit planning tool.
Description: An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
Study: NCT02669654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day-care management of Severe Pneumonia
Description: Day-care management of Severe Pneumonia
Study: NCT03670745

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No planning tool
Study: NCT04889885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT)
Description: HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
Study: NCT03943186

Intervention type: DEVICE
Intervention: Ectoin Lozenges Honey Lemon
Description: application of Ectoin Lozenges (EHT02) in accordance with the instructions for use

Intervention type: DEVICE
Intervention: Hyaluronic Acid/Icelandic moss Lozenges
Description: application of the lozenges in accordance with the instructions for use
Study: NCT00737308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ceramic crown
Description: Zirconia
Study: NCT01023178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17beta Estradiol
Description: Oral pill given daily at increasing doses every 6 months for 18 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated estrogens
Description: Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
Study: NCT03373799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based Rehabilitation Program
Description: In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
Study: NCT01023178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17Beta Estradiol - transdermal
Description: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone, micronized
Description: Given starting at 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone, micronized
Description: Given starting at 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone, micronized
Description: Given starting at 18 months
Study: NCT04044079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
Study: NCT01157858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: 40 mg every 28 days IM
Study: NCT05513612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T cells
Description: CAR-T cells will be infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study: NCT02404831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based PR
Description: Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
Study: NCT03373799

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist-Supervised Rehabilitation Program
Description: In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
Study: NCT02404831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based PR
Description: Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.